Update on Investigational Drugs
Originally presented at HOPA's 13th Annual Conference, March 2017.
This session will discuss a variety of agents, including mechanism of action, and recent published information when applicable. The focus will be on medications that are in early phase trials. The information in this session is applicable for most attendees.
- Discuss current and emerging pathways targeted at the development of anticancer drugs.
- Describe the rationale and recent clinical findings for newly developed therapies.
Casey Williams, PharmD BCOP FHOPA
Casey Williams received a bachelor of science degree in biology and chemistry from Buena Vista University in 1996 and the PharmD degree from Creighton University in 2000; he subsequently completed his PGY-1 residency in pharmacy practice at the University of North Carolina and his PGY-2 oncology practice residency at the University of Texas/Audie L. Murphy Memorial VA Hospital. He has clinical faculty appointments at the University of Kansas School of Pharmacy, South Dakota State University School of Pharmacy, and the University of South Dakota School of Medicine. His current research focus is in the use of cancer genomics and translational therapeutics to better understand the role that specific genes have on the activity of various cancer treatments.
This activity has been approved for .125 CEUs
Research; Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.
This activity has been approved for .1 CEU
This course is also included as part of the Best of AC2017 Bundle product.
Release Date: August 31, 2017
Expiration Date: March 29, 2020